As filed with the Securities and Exchange Commission on March 15, 2022
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Unity Biotechnology, Inc.
(Exact name of Registrant as specified in its charter)
| | | |
Delaware (State or other jurisdiction of incorporation or organization) | | 2834 (Primary Standard Industrial Classification Code Number) | 26-4726035 (I.R.S. Employer Identification Number) |
285 East Grand Avenue
South San Francisco, CA 94080
(650) 416-1192
(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)
2018 Incentive Award Plan
2018 Employee Stock Purchase Plan
(Full Title of the Plan)
Anirvan Ghosh, Ph.D. Chief Executive Officer
Unity Biotechnology, Inc.
285 East Grand Avenue
South San Francisco, CA 94080
(650) 416-1192
(Name, address, including zip code, and telephone number, including area code, of agent for service)
| | |
Copy to: |
Brian J. Cuneo, Esq. Latham & Watkins LLP 140 Scott Drive Menlo Park, CA 94025 Telephone: (650) 328-4600 Facsimile: (650) 463-2600 |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | | Accelerated filer | ☐ |
Non-accelerated filer | ☒ | | Smaller reporting company | ☒ |
| | | Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
Proposed sale to take place as soon after the effective date of the
registration statement as awards under the plans are exercised and/or vest.
EXPLANATORY NOTE
This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 3,812,884 shares of the Registrant’s common stock issuable under the following employee benefit plans for which Registration Statements of the Registrant on Form S-8 (File Nos. 333-224726, 333-230086, 333-237088 and 333-254619) are effective: (i) the 2018 Incentive Award Plan, as a result of (x) the operation of an automatic annual increase provision therein, which added 3,149,595 of common stock, and (y) 33,370 additional shares available under the 2018 Incentive Award Plan, primarily resulting from repurchases of awards, and (ii) the 2018 Employee Stock Purchase Plan, as a result of the operation of an automatic annual increase provision therein, which added 629,919 shares of common stock.
INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON
FORM S-8
Pursuant to Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 7, 2018 (File No. 333-224726), March 6, 2019 (File No. 333-230086), March 11, 2020 (File No. 333-237088) and March 23, 2021(File No. 333-254619) are incorporated by reference herein.
Exhibit Index
# Indicates management contract or compensatory plan.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in South San Francisco, California.
| Unity Biotechnology, Inc. |
| | |
Date: March 15, 2022 | By: | | /s/ Anirvan Ghosh |
| | | Anirvan Ghosh, Ph.D. Chief Executive Officer |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Anirvan Ghosh, Ph.D., Alexander Nguyen, and Lynne Sullivan, his or her true and lawful attorneys-in-fact and agents, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons on behalf of the Registrant, in the capacities and on the dates indicated.
Signature | | Title | | Date |
| | |
/s/ Anirvan Ghosh Anirvan Ghosh, Ph.D. | | Chief Executive Officer and Director (Principal Executive Officer) | | March 15, 2022 |
| | |
/s/ Lynne Sullivan Lynne Sullivan | | Chief Financial Officer (Principal Financial and Accounting Officer) | | March 15, 2022 |
/s/ Keith R. Leonard Jr. Keith R. Leonard Jr. | | Chairman | | March 15, 2022 |
| | |
/s/ Paul L. Berns Paul L. Berns | | Director | | March 15, 2022 |
| | |
/s/ Kristina M. Burow Kristina M. Burow | | Director | | March 15, 2022 |
| | |
/s/ Graham K. Cooper Graham K. Cooper | | Director | | March 15, 2022 |
| | |
/s/ Nathaniel E. David Nathaniel E. David, Ph.D. | | Director | | March 15, 2022 |
| | | | |
/s/ Gilmore O’Neill | | Director | | March 15, 2022 |
Gilmore O’Neill, M.B. | | | | |
| | | | |
/s/ Margo Roberts | | Director | | March 15, 2022 |
Margo Roberts, Ph.D. | | | | |
| | | | |
/s/ Camille D. Samuels | | Director | | March 15, 2022 |
Camille D. Samuels | | | |
| | | |